FIX-Padua基因治疗中凝血因子IX活性检测差异
该研究首次评估了接受FIX-Padua基因转移的血友病B患者血浆中,五种常用凝血试验检测的FIX:C。结果显示中心实验室FIX:C绝对值持续低于本地实验室,且不同检测方法间存在差异,提示FIX-Padua蛋白本身导致检测变异性,与基因治疗来源无关。
要点
- 中心实验室FIX:C绝对值持续低于本地实验室。
- 发色底物法FIX:C低于任何一期法。
- FIX-Padua蛋白本身导致检测差异,与基因治疗无关。
核心结论
- FIX-Padua转基因产物和rHFIX-Padua蛋白在不同检测试剂下FIX:C存在差异,表明变异性源于FIX-Padua蛋白本身,而非基因治疗特异性。
研究设计与样本
- 研究比较了中心实验室(n=1)和本地实验室(n=5)的FIX:C,以及四种常用一期法和一种发色底物法。
- 还测试了用纯化rHFIX-Padua或rHFIX(nonacog alfa)加标的混合先天性FIX缺陷血浆样本,FIX:C浓度约为20%至40%。
主要发现
- 本地实验室FIX:C结果与中心实验室强相关,但中心实验室绝对值持续较低。
- 在五种FIX:C检测中,接受fidanacogene elaparvovec基因转移的受试者呈现一致的FIX:C模式。
- 中心实验室使用Actin FSL APTT试剂导致FIX:C值低于其他测试的APTT试剂。
- 发色底物法测定的FIX:C低于任何一期法。
- rHFIX-Padua加标样本显示类似结果;而rHFIX-nonacog alfa在所有一期法中测定值在预期值的25%以内,发色底物法低于25%。
临床怎么用
- 临床监测FIX-Padua基因治疗患者时,应意识到不同检测方法间FIX:C存在差异,中心实验室值可能较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited information exists regarding the factor IX (FIX) coagulant activity (FIX:C) measured by different assays following FIX-Padua gene therapy. OBJECTIVE: Assess for the first time FIX:C in five commonly used coagulation assays in plasma samples from hemophilia B subjects receiving FIX-Padua gene transfer. METHODS: FIX:C was compared between central (n = 1) and local laboratories (n = 5) in the study, and across four commonly used FIX:C one-stage assays and one FIX:C chromogenic assay. For comparison, samples of pooled congenital FIX-deficient plasma spiked with purified recombinant human FIX (rHFIX)-Padua protein or rHFIX (nonacog alfa) to obtain FIX:C concentrations from ~20% to ~40% were tested. RESULTS: FIX:C results at local laboratories strongly correlated with central laboratory results. However, absolute values at the central laboratory were consistently lower than those at local laboratories. Across five different FIX:C assays, a consistent pattern of FIX:C was observed for subjects receiving fidanacogene elaparvovec-expressed gene transfer. Use of Actin FSL activated partial thromboplastin time (APTT) reagent in the central laboratory resulted in lower FIX:C values compared with other APTT reagents tested. The chromogenic assay determined lower FIX:C than any of the one-stage assays. The rHFIX-Padua protein-spiked samples showed similar results. In contrast, FIX:C results for rHFIX-nonacog alfa measured within 25% of expected for all one-stage assays and below 25% in the chromogenic assay. CONCLUSIONS: Assay-based differences in FIX:C were observed for fidanacogene elaparvovec transgene product and rHFIX-Padua protein, suggesting the variable FIX:C determined with different assay reagents is inherent to the FIX-Padua protein and is not specific to gene therapy-derived FIX-Padua.
引用
- Robinson MM, George LA, Carr ME, et al. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021. PMID: 33636038. doi:10.1111/jth.15281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。